Featured News See All November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA November 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 November 6, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Year All202420232022202120202019201820172016201520142013201220112009 Aug 01, 2024 REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 Jul 25, 2024 REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights Jun 24, 2024 REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients Jun 18, 2024 REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II Jun 12, 2024 REGENXBIO Announces Leadership Transition Jun 05, 2024 REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference May 10, 2024 REGENXBIO to Participate in Upcoming Investor Conferences
Jul 25, 2024 REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
Jun 24, 2024 REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
Jun 18, 2024 REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
